NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects

NCT00810732

CompletedPhase 2

Sponsor: Pfizer

Conditions: Chronic Kidney Disease

Interventions: Open, Nifedipine, Placebo

Countries: United Kingdom

This study is being conducted to evaluate sitaxsentan dosing in subjects with chronic kidney disease.

Eligibility overview

Sex: ALL

Age: 18 Years to 70 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Has stage 1-5 chronic kidney disease (CKD) as defined by the Kidney Disease Outcomes Quality Initiative (K/DOQI) with proteinuria, including any of the following aetiologies: immunoglobulin (IgA) nephropathy, polycystic kidney disease (PCKD), congenital abnormalities, reflux nephropathy, focal segmental glomerulosclerosis, minimal change nephropathy, and membranous nephropathy.

Exclusion Criteria:

* Required peritoneal dialysis or haemodialysis.
* Has kidney disease due to diabetes mellitus, vasculitis, systemic lupus erythematosus, or known renovascular disease; antiglomerular basement membrane disease; or is on immunosuppressive medication.

Locations (2)

Edinburgh, Scotland, United Kingdom
Edinburgh, Scotland, United Kingdom